Literature DB >> 28428269

Low frequency mutations in ribosomal proteins RPL10 and RPL5 in multiple myeloma.

Isabel J F Hofman1, Stephanie Patchett2, Mark van Duin3, Ellen Geerdens4,5, Jelle Verbeeck1, Lucienne Michaux6, Michel Delforge7, Pieter Sonneveld3, Arlen W Johnson2, Kim De Keersmaecker8.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28428269      PMCID: PMC5541886          DOI: 10.3324/haematol.2016.162198

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

Review 1.  Molecular pathogenesis of multiple myeloma and its premalignant precursor.

Authors:  W Michael Kuehl; P Leif Bergsagel
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

Review 2.  The genetic architecture of multiple myeloma.

Authors:  Gareth J Morgan; Brian A Walker; Faith E Davies
Journal:  Nat Rev Cancer       Date:  2012-04-12       Impact factor: 60.716

3.  Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations.

Authors:  Viktor Ljungström; Diego Cortese; Emma Young; Tatjana Pandzic; Larry Mansouri; Karla Plevova; Stavroula Ntoufa; Panagiotis Baliakas; Ruth Clifford; Lesley-Ann Sutton; Stuart J Blakemore; Niki Stavroyianni; Andreas Agathangelidis; Davide Rossi; Martin Höglund; Jana Kotaskova; Gunnar Juliusson; Chrysoula Belessi; Nicholas Chiorazzi; Panagiotis Panagiotidis; Anton W Langerak; Karin E Smedby; David Oscier; Gianluca Gaidano; Anna Schuh; Frederic Davi; Christiane Pott; Jonathan C Strefford; Livio Trentin; Sarka Pospisilova; Paolo Ghia; Kostas Stamatopoulos; Tobias Sjöblom; Richard Rosenquist
Journal:  Blood       Date:  2015-12-16       Impact factor: 22.113

4.  Initial genome sequencing and analysis of multiple myeloma.

Authors:  Michael A Chapman; Michael S Lawrence; Jonathan J Keats; Kristian Cibulskis; Carrie Sougnez; Anna C Schinzel; Christina L Harview; Jean-Philippe Brunet; Gregory J Ahmann; Mazhar Adli; Kenneth C Anderson; Kristin G Ardlie; Daniel Auclair; Angela Baker; P Leif Bergsagel; Bradley E Bernstein; Yotam Drier; Rafael Fonseca; Stacey B Gabriel; Craig C Hofmeister; Sundar Jagannath; Andrzej J Jakubowiak; Amrita Krishnan; Joan Levy; Ted Liefeld; Sagar Lonial; Scott Mahan; Bunmi Mfuko; Stefano Monti; Louise M Perkins; Robb Onofrio; Trevor J Pugh; S Vincent Rajkumar; Alex H Ramos; David S Siegel; Andrey Sivachenko; A Keith Stewart; Suzanne Trudel; Ravi Vij; Douglas Voet; Wendy Winckler; Todd Zimmerman; John Carpten; Jeff Trent; William C Hahn; Levi A Garraway; Matthew Meyerson; Eric S Lander; Gad Getz; Todd R Golub
Journal:  Nature       Date:  2011-03-24       Impact factor: 49.962

5.  Mutations driving CLL and their evolution in progression and relapse.

Authors:  Dan A Landau; Eugen Tausch; Amaro N Taylor-Weiner; Chip Stewart; Johannes G Reiter; Jasmin Bahlo; Sandra Kluth; Ivana Bozic; Mike Lawrence; Sebastian Böttcher; Scott L Carter; Kristian Cibulskis; Daniel Mertens; Carrie L Sougnez; Mara Rosenberg; Julian M Hess; Jennifer Edelmann; Sabrina Kless; Michael Kneba; Matthias Ritgen; Anna Fink; Kirsten Fischer; Stacey Gabriel; Eric S Lander; Martin A Nowak; Hartmut Döhner; Michael Hallek; Donna Neuberg; Gad Getz; Stephan Stilgenbauer; Catherine J Wu
Journal:  Nature       Date:  2015-10-14       Impact factor: 49.962

6.  RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response.

Authors:  I J F Hofman; M van Duin; E De Bruyne; L Fancello; G Mulligan; E Geerdens; E Garelli; C Mancini; H Lemmens; M Delforge; P Vandenberghe; I Wlodarska; A Aspesi; L Michaux; K Vanderkerken; P Sonneveld; K De Keersmaecker
Journal:  Leukemia       Date:  2016-12-02       Impact factor: 11.528

7.  Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.

Authors:  Jens G Lohr; Petar Stojanov; Scott L Carter; Peter Cruz-Gordillo; Michael S Lawrence; Daniel Auclair; Carrie Sougnez; Birgit Knoechel; Joshua Gould; Gordon Saksena; Kristian Cibulskis; Aaron McKenna; Michael A Chapman; Ravid Straussman; Joan Levy; Louise M Perkins; Jonathan J Keats; Steven E Schumacher; Mara Rosenberg; Gad Getz; Todd R Golub
Journal:  Cancer Cell       Date:  2014-01-13       Impact factor: 31.743

8.  Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.

Authors:  Niccolo Bolli; Hervé Avet-Loiseau; David C Wedge; Peter Van Loo; Ludmil B Alexandrov; Inigo Martincorena; Kevin J Dawson; Francesco Iorio; Serena Nik-Zainal; Graham R Bignell; Jonathan W Hinton; Yilong Li; Jose M C Tubio; Stuart McLaren; Sarah O' Meara; Adam P Butler; Jon W Teague; Laura Mudie; Elizabeth Anderson; Naim Rashid; Yu-Tzu Tai; Masood A Shammas; Adam S Sperling; Mariateresa Fulciniti; Paul G Richardson; Giovanni Parmigiani; Florence Magrangeas; Stephane Minvielle; Philippe Moreau; Michel Attal; Thierry Facon; P Andrew Futreal; Kenneth C Anderson; Peter J Campbell; Nikhil C Munshi
Journal:  Nat Commun       Date:  2014       Impact factor: 14.919

9.  The ribosomal protein gene RPL5 is a haploinsufficient tumor suppressor in multiple cancer types.

Authors:  Laura Fancello; Kim R Kampen; Isabel J F Hofman; Jelle Verbeeck; Kim De Keersmaecker
Journal:  Oncotarget       Date:  2017-02-28

10.  Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.

Authors:  Brian A Walker; Eileen M Boyle; Christopher P Wardell; Alex Murison; Dil B Begum; Nasrin M Dahir; Paula Z Proszek; David C Johnson; Martin F Kaiser; Lorenzo Melchor; Lauren I Aronson; Matthew Scales; Charlotte Pawlyn; Fabio Mirabella; John R Jones; Annamaria Brioli; Aneta Mikulasova; David A Cairns; Walter M Gregory; Ana Quartilho; Mark T Drayson; Nigel Russell; Gordon Cook; Graham H Jackson; Xavier Leleu; Faith E Davies; Gareth J Morgan
Journal:  J Clin Oncol       Date:  2015-08-17       Impact factor: 44.544

View more
  14 in total

1.  Identification of RPL5 gene variants and the risk of hepatic vein thrombosis in Saudi patients.

Authors:  Fathelrahman M Hassan; Afnan A Alsultan; Faisal Alzahrani; Waleed H Albuali; Dalal K Bubshait; Elfadil M Abass; Mudathir A Elbasheer; Abdulmohsen A Alkhanbashi
Journal:  Saudi Med J       Date:  2021-09       Impact factor: 1.422

2.  Cancer-associated mutations in the ribosomal protein L5 gene dysregulate the HDM2/p53-mediated ribosome biogenesis checkpoint.

Authors:  Ines Oršolić; Slađana Bursać; Deana Jurada; Irena Drmić Hofman; Zlatko Dembić; Jiri Bartek; Ivana Mihalek; Siniša Volarević
Journal:  Oncogene       Date:  2020-02-27       Impact factor: 9.867

Review 3.  Post-transcriptional diversity in riboproteins and RNAs in aging and cancer.

Authors:  Jurandir Cruz; Bernardo Lemos
Journal:  Semin Cancer Biol       Date:  2021-08-30       Impact factor: 15.707

4.  Smoothened-activating lipids drive resistance to CDK4/6 inhibition in Hedgehog-associated medulloblastoma cells and preclinical models.

Authors:  Vikas Daggubati; Jordan Hochstelter; Anirudh Bommireddy; Abrar Choudhury; Alexis Leigh Krup; Pervinder Kaur; Pakteema Tong; Amy Li; Libin Xu; Jeremy F Reiter; David R Raleigh
Journal:  J Clin Invest       Date:  2021-03-15       Impact factor: 19.456

Review 5.  Treating hematological malignancies with drugs inhibiting ribosome biogenesis: when and why.

Authors:  Enrico Derenzini; Alessandra Rossi; Davide Treré
Journal:  J Hematol Oncol       Date:  2018-05-31       Impact factor: 17.388

6.  Whole-genome sequencing of multiple myeloma reveals oncogenic pathways are targeted somatically through multiple mechanisms.

Authors:  Phuc H Hoang; Sara E Dobbins; Alex J Cornish; Daniel Chubb; Philip J Law; Martin Kaiser; Richard S Houlston
Journal:  Leukemia       Date:  2018-04-09       Impact factor: 11.528

Review 7.  How Ribosomes Translate Cancer.

Authors:  Sergey O Sulima; Isabel J F Hofman; Kim De Keersmaecker; Jonathan D Dinman
Journal:  Cancer Discov       Date:  2017-09-18       Impact factor: 39.397

Review 8.  The nucleolus, an ally, and an enemy of cancer cells.

Authors:  Dariusz Stępiński
Journal:  Histochem Cell Biol       Date:  2018-08-13       Impact factor: 4.304

9.  MeCP2 facilitates breast cancer growth via promoting ubiquitination-mediated P53 degradation by inhibiting RPL5/RPL11 transcription.

Authors:  DongDong Tong; Jing Zhang; XiaoFei Wang; Qian Li; Li Ying Liu; Juan Yang; Bo Guo; Lei Ni; LingYu Zhao; Chen Huang
Journal:  Oncogenesis       Date:  2020-06-01       Impact factor: 7.485

10.  Role of uL3 in the Crosstalk between Nucleolar Stress and Autophagy in Colon Cancer Cells.

Authors:  Annalisa Pecoraro; Pietro Carotenuto; Brunella Franco; Rossella De Cegli; Giulia Russo; Annapina Russo
Journal:  Int J Mol Sci       Date:  2020-03-20       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.